Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
复制标题
DOI：
10.1016/j.bbmt.2019.09.015
复制
发表时间：
2020-01-01
影响因子：
4.3
通讯作者：
McCarthy, Philip L.
中科院分区：
文献类型：
--
作者：
Holstein, Sarah A.;Al-Kadhimi, Zaid;McCarthy, Philip L.
第三届年度血液和骨髓移植临床试验网络（BMT CTN）骨髓瘤微小残留病和免疫分析小组间研讨会于2018年11月29日在美国血液学会（ASH）年会上举行。本次研讨会重点介绍了骨髓瘤中最小残留病（MRD）评估和免疫分析（IP）的最新研究，以及MRD作为替代终点发展所固有的统计和监管问题的讨论。在本报告中，我们提供了研讨会的总结，并重点介绍了将MRD和IP评估整合到试验设计和临床实践中。(C)2019年美国移植和细胞治疗学会。爱思唯尔公司出版
The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.